Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human safety, tolerability, and pharmacokinetics study of MR-L45 in healthy adults
NL-OMON61028Phase 1Recruiting
- Sponsor
- Mironid
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of MR-L45 in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Mironid. Started Jul 2026; status: recruiting.
02
Drugs
MR-L45
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NL-OMON61028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61028.